Polyclonal IgM and IgA block in vitro complement deposition mediated by anti-ganglioside antibodies in autoimmune neuropathies

International Immunopharmacology

Volumn 40, Issue , 2016, Pages 11-15

  Sudo, Makoto ^a   Miyaji, Kazuki ^a   Späth, Peter J ^b   Morita Matsumoto, Kana ^c   Yamaguchi, Yoshiki ^c   Yuki, Nobuhiro ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF BERN   (Switzerland)

^c RIKEN   (Japan)

Author keywords

Anti ganglioside antibody; Complement; Guillain Barr syndrome; Intravenous immunoglobulin; Multifocal motor neuropathy

Indexed keywords

COMPLEMENT COMPONENT C3; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; ANTI-IGG; ANTI-IGM; ANTIIDIOTYPIC ANTIBODY; COMPLEMENT; IMMUNOGLOBULIN;

ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DRUG EFFICACY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; INHIBITORY CONCENTRATION; MOTOR NEUROPATHY; PATIENT SAFETY; PRIORITY JOURNAL; BLOOD; IMMUNOLOGY;

ANTIBODIES, ANTI-IDIOTYPIC; COMPLEMENT SYSTEM PROTEINS; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS;

EID: 84983456862     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2016.08.019     Document Type: Article

References (17)

1. [1] Kaveri, S.V., Lacroix-Desmazes, S., Bayry, J., The antiinflammatory IgG. N. Engl. J. Med. 359 (2008), 307–309.
2. [2] Tackenberg, B., Jelčić, I., Baerenwaldt, A., Oertel, W.O., Sommer, N., Nimmerjahn, F., Lϋnemann, J.D., Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 4788–4792.
3. [3] Vlam, L., van der Pol, W.L., Cats, E.A., Straver, D.C., Piepers, S., Franssen, H., van den Berg, L.H., Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat. Rev. Immunol. 8 (2011), 48–58.
4. [4] Yuki, N., Hartung, H.P., Guillain–Barré syndrome. N. Engl. J. Med. 366 (2012), 2294–2304.
5. [5] Yuki, N., Watanabe, H., Nakajima, T., Späth, P.J., IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J. Neurol. Nerosurg. Psychiatry 82 (2011), 87–91.
6. [6] Boes, M., Schmidt, T., Linkemann, K., Beaudette, B.C., Marshak-Rothstein, A., Chen, J., Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 1184–1189.
7. [7] Tyomin, P., Krapivkine, A., Perminov, V., Nikamorova, M., High dose of intravenous immune globulin (IVIG) in the treatment of infantile spasms and Lennox-Gastaut syndrome. Epilepsia, 38, 1997, 39.
8. [8] Brunner, R., Rinner, W., Haberler, C., Kitzberger, R., Sycha, T., Herkner, H., Warszawska, J., Madl, C., Holzinger, U., Early treatment with IgM-enriched intravenous immune globulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial. Crit. Care, 17, 2013, R213.
9. [9] Ius, F., Sommer, W., Kieneke, D., Tudorache, I., Kühn, C., Avsar, M., Siemeni, T., Salman, J., Erdfelder, C., Verboom, M., Kielstein, J., Tecklenburg, A., Greer, M., Hallensleben, M., Blasczyk, R., Schwerk, N., Gottlieb, J., Welte, T., Haverich, A., Warnecke, G., IgM-enriched human intravenous immunoglobulin-based treatment of patients with early donor specific anti-HLA antibodies after lung transplantation. Transplantation, 2015 Dec 28.
10. [10] Rieben, R., Roos, A., Muizert, Y., Tinguely, C., Gerritsen, A.F., Daha, M.R., Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 93 (1999), 942–951.
11. [11] Bar-Dayan, Y., Bonnin, E., Bloch, M., Schweitzer, R., Ravid, M., Kazatchkine, M.D., Kaveri, S.V., Neutralization of disease associated autoantibodies by an immunoglobulin M- and immunoglobulin A-enriched human intravenous immunoglobulin preparation. Scand. J. Immunol. 51 (2000), 408–414.
12. [12] Yuki, N., Tagawa, Y., Irie, F., Hirabayashi, Y., Handa, S., Close association of Guillain–Barré syndrome with antibodies to minor monosialogangliosides GM1b and GM1α. J. Neuroimmunol. 74 (1997), 30–34.
13. [13] Sudo, M., Yamaguchi, Y., Späth, P.J., Matsumoto-Morita, K., Ong, B.K., Shahrizaila, N., Yuki, N., Different IVIG glycoforms affect in vitro inhibition of anti-ganglioside antibody-mediated complement deposition. PLoS One, 9, 2014, e107772.
14. [14] Kaveri, S.V., Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun. Rev. 11 (2012), 792–794.
15. [15] Hurez, V., Kaveri, S.V., Kazatchkine, M.D., Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur. J. Immunol. 23 (1993), 783–789.
16. [16] Hurez, V., Kazatchkine, M.D., Vassilev, T., Ramanathan, S., Pashov, A., Basuyaux, B., de Kozak, Y., Bellon, B., Kaveri, S.V., Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 90 (1997), 4004–4013.
17. [17] Vassilev, T., Mihaylova, N., Voynova, E., Nikolova, M., Kazatchkine, M., Kaveri, S., IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice. Clin. Exp. Immunol. 145 (2006), 108–115.